Asset information about Insmed Inc (INSM)

Here are two polished descriptions you can use—one short (elevator pitch) and one longer (for a website or investor summary). I avoided specific pipeline molecule names beyond the well-known marketed product; if you want more detail (leadership, financials, or an expanded product/pipeline section) I can add it.

Short (1–2 sentences)
Insmed Inc. is a publicly traded biopharmaceutical company (Nasdaq: INSM) focused on developing and commercializing therapies for people with serious and rare diseases, especially hard-to-treat pulmonary infections. Its flagship marketed product, ARIKAYCE (amikacin liposome inhalation suspension), treats refractory Mycobacterium avium complex (MAC) lung disease; the company advances additional clinical-stage programs using inhaled and targeted delivery approaches.

Longer (paragraph)
Insmed Inc. is a global biopharmaceutical company headquartered in Bridgewater, New Jersey, that develops and commercializes therapies for patients with rare and serious diseases, with a strong focus on pulmonary and infectious diseases. The company’s flagship product, ARIKAYCE, is an inhaled liposomal formulation of amikacin approved for the treatment of refractory Mycobacterium avium complex (MAC) lung disease and serves as a commercial and clinical platform for the organization. Insmed pursues additional clinical-stage programs that leverage targeted delivery technologies—including inhaled and liposomal approaches—to address unmet needs in rare respiratory and systemic conditions. The company combines R&D and clinical development with commercial capabilities, patient-support services, and strategic partnerships to bring therapies to underserved patient populations.

If you’d like, I can tailor one of these for a specific audience (investors, patients, partners) or add up-to-date corporate facts (leadership, financial highlights, or full pipeline details).